+49 30 838 53221
Introduction: Schizophrenia is a chronic psychiatric disorder. Current antipsychotic therapy has limited efficacy and association with severe side effects, e.g. motor adverse effects, weight gain and changes in body fat composition. Dopamine D2 receptor partial
agonists represent a sophisticated option for effective antipsychotic treatment with diminished adverse effects. Our previous in vitro and in vivo data revealed that the terguride derivative 2-bromoterguride (2-BT) is a partial Agonist at dopamine D2 receptors with promising antipsychotic characteristics.Methods: Here, chronic effects of 2-BT (0.1 and 0.3 mg/kg for 21 days; twice daily) on food and water intake, body weight and fat tissues were examined in female Sprague Dawley rats with the same doses as used before. Additionally, we investigated the influence of chronic 2-BT on spontaneous behaviour in the open field box and cataleptic behaviour in the bar and grid test. The positive control was the atypical antipsychotic olanzapine (2 mg/kg).Results: In contrast to olanzapine, chronic 2-BT administration did not induce changes in food and water intake, Body weight and body fat composition compared to vehicle group. Similar to acute conditions, 2-BT brought on no cataleptic behaviour but decreased spontaneous locomotion. Conclusions: Apparently, 2-BT possesses no liability to weight gain and does not Change body fat composition. Both doses of 2-BT seem to be slightly sedative without inducing Motor adverse effects. The present study confirms our previous observations that the D2 receptor partial agonist 2-BT may be a promising candidate for the treatment of schizophrenia with minor adverse effects.